Aligos Therapeutics (STU:5WK0) Other Current Liabilities: €4.11 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5WK0 Aligos Therapeutics Inc STU:5WK0
44 GF Score
Price €5.85
GF Value €28.54
! 5 Warning Signs
View Full Analysis

What is Aligos Therapeutics Other Current Liabilities?

Aligos Therapeutics STU:5WK0 +1.04% 44 Other Current Liabilities is €4.11 Mil as of Jun. 2026. GuruFocus rates STU:5WK0 with a GF Score™ of 44/100 and a GF Value™ of €28.54. The stock has 5 warning signs investors should review.

Aligos Therapeutics's other current liabilities for the quarter that ended in Jun. 2026 was €4.11 Mil.

Aligos Therapeutics's quarterly other current liabilities declined from Dec. 2025 (€6.37 Mil) to Mar. 2026 (€3.65 Mil) but then increased from Mar. 2026 (€3.65 Mil) to Jun. 2026 (€4.11 Mil).

Aligos Therapeutics's annual other current liabilities declined from Dec. 2023 (€6.12 Mil) to Dec. 2024 (€6.10 Mil) but then increased from Dec. 2024 (€6.10 Mil) to Dec. 2025 (€6.37 Mil).

Aligos Therapeutics Other Current Liabilities Related Terms

Aligos Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics Other Current Liabilities Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 5.85 6.01 6.12 6.10 6.37

Aligos Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 4.50 6.37 3.65 4.11
STU:5WK0
44GF Score
Aligos Therapeutics Inc STU:5WK0
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aligos Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €4.11 Mil mean?
Aligos Therapeutics (STU:5WK0) has a Other Current Liabilities of €4.11 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aligos Therapeutics.
Is Aligos Therapeutics' Other Current Liabilities too high?
Aligos Therapeutics' current Other Current Liabilities is €4.11 Mil. Overall, Aligos Therapeutics has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Other Current Liabilities compare to CRVO and PVCT?
Aligos Therapeutics' Other Current Liabilities of €4.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aligos Therapeutics. Aligos Therapeutics's current Other Current Liabilities is €4.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Aligos Therapeutics (STU:5WK0) has a current Other Current Liabilities of €4.11 Mil. The stock's GF Value™ is €28.54, compared to a current price of €5.85 — trading 79.5% below its estimated fair value. The current Other Current Liabilities is €4.11 Mil. Aligos Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Aligos Therapeutics (STU:5WK0), the current Other Current Liabilities is €4.11 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued. The current stock price of €5.85 is trading 79.5% below its estimated GF Value™ of €28.54.

Key valuation signals for STU:5WK0:

  • Other Current Liabilities: €4.11 Mil
  • GF Value™: €28.54 vs. price of €5.85 (79.5% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges ALGS:USA
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
44GF Score

Get the complete analysis for STU:5WK0

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.85
Price
€28.54
GF Value